Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

Graham Jackson, MD, PhD
Published: Friday, Mar 24, 2017



Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

There are many challenges that oncologists are still facing in this field, including the fact that there is not a 100% cure rate, Jackson explains. There are a lot of patients with durable responses who have low-risk disease; however, for patients with high-risk disease who go through treatment lines very quickly, they are mostly transient responses, leading researchers to believe that this subpopulation is a higher unmet need.

Additionally, patients become refractory to several therapies. Results of the STORM study, which explored selinexor (KPT-330) in this population of patients, are intriguing, he adds. Novel agents moving through the pipeline are likely to lead excitement in the field.
 
SELECTED
LANGUAGE


Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

There are many challenges that oncologists are still facing in this field, including the fact that there is not a 100% cure rate, Jackson explains. There are a lot of patients with durable responses who have low-risk disease; however, for patients with high-risk disease who go through treatment lines very quickly, they are mostly transient responses, leading researchers to believe that this subpopulation is a higher unmet need.

Additionally, patients become refractory to several therapies. Results of the STORM study, which explored selinexor (KPT-330) in this population of patients, are intriguing, he adds. Novel agents moving through the pipeline are likely to lead excitement in the field.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x